IceCure Medical ProSense Revenue Surges 30% in Q1 2026 as Cryoablation Technology Gains Traction

Key Takeaways

• IceCure Medical’s ProSense cryoablation systems generated 30%+ revenue growth in Q1 2026 versus Q1 2025
• The company participated in the Society of Breast Imaging Symposium 2026 to showcase minimally-invasive tumor treatment technology
• ProSense offers an alternative to surgical tumor removal by destroying tumors through controlled freezing

---

IceCure Medical Ltd. (Nasdaq: ICCM) reported preliminary Q1 2026 revenue growth exceeding 30% for its ProSense cryoablation systems compared to the same period in 2025, signaling increased adoption of minimally-invasive cancer treatment alternatives.

The Caesarea, Israel-based medical device company announced the preliminary, unaudited revenue estimates on April 21, 2026, while participating in the Society of Breast Imaging Symposium 2026. The revenue increase encompasses both ProSense systems and associated cryoprobes used in the tumor ablation procedures.

Growing Market for Cryoablation Technology

IceCure Medical develops cryoablation technology that destroys tumors by freezing tissue, offering patients an alternative to traditional surgical tumor removal. The ProSense system represents a shift toward minimally-invasive oncology treatments that can reduce patient recovery time and procedural complications.

The company’s participation in the Society of Breast Imaging Symposium demonstrates its focus on expanding ProSense adoption among breast imaging specialists and interventional radiologists. These medical conferences serve as crucial platforms for showcasing clinical evidence and building relationships with key opinion leaders in oncology.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications

The 30% revenue growth suggests increasing physician and patient acceptance of cryoablation as a viable treatment option. This growth trajectory positions IceCure Medical favorably in the expanding minimally-invasive cancer treatment market, which continues to gain traction as healthcare systems seek cost-effective alternatives to traditional surgery.

The preliminary nature of these results indicates final Q1 2026 financial reporting will provide more detailed insights into the company’s performance and future growth prospects. Investors and healthcare stakeholders will be monitoring whether this growth momentum continues throughout 2026.

---

Frequently Asked Questions

What is ProSense cryoablation technology?

ProSense is IceCure Medical’s minimally-invasive system that destroys tumors by freezing them, offering an alternative to surgical tumor removal with potentially shorter recovery times.

How significant is the 30% revenue increase?

The 30%+ growth in Q1 2026 versus Q1 2025 indicates strong market adoption of cryoablation technology and suggests increasing physician confidence in minimally-invasive tumor treatment options.

When will final Q1 2026 results be available?

IceCure Medical has provided preliminary, unaudited estimates for Q1 2026. Final financial results will be released in the company’s official quarterly earnings report.

Related coverage

• Eli Lilly raises 2026 revenue guidance on Mounjaro demand
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Vabysmo gains EU approval for retinal vein occlusion: what changes next